Adherence and persistence in the use of statins and ezetimibe over 8 years in a real-life study

References

• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Yebyo HG, Aschmann HE, Kaufmann M, et al. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28.
   PubMed Web of Science ®Google Scholar
• Chaudhry HJ, McDermott B. Recognizing and improving patient nonadherence to statin therapy. Curr Atheroscler Rep. 2008;10(1):19–24.
   PubMed Web of Science ®Google Scholar
• Casula M, Tragni E, Catapano AL. Adherence to lipid-lowering treatment: the patient perspective. Patient Prefer Adherence. 2012;6:805–814.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–S45.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9(2):129–169.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Smith DA, Mehta AE, AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis, et al. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis: executive summary. Endocr Pract. 2012;18(2):269–293.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, ESC Scientific Document Group, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, ESC Scientific Document Group, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1046–e81.
   PubMed Web of Science ®Google Scholar
• De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003;2(4):323.
   PubMedGoogle Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Sattler EL, Lee JS, Perri M. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383–399.
   PubMed Web of Science ®Google Scholar
• Hansen RA, Kim MM, Song L, et al. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413–422.
   PubMed Web of Science ®Google Scholar
• Lemstra M, Blackburn D. Nonadherence to statin therapy: discontinuation after a single fill. Can J Cardiol. 2012;28(5):567–573.
   PubMed Web of Science ®Google Scholar
• Allonen J, Nieminen MS, Lokki M, et al. Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol. 2012;35(11):E22–7.
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530.
   PubMed Web of Science ®Google Scholar
• Forbes CA, Deshpande S, Sorio-Vilela F, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin. 2018;34(9):1613–1625.
   PubMed Web of Science ®Google Scholar
• WHO International Working Group for Drug Statistics Methodology WCCfDSM, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. Introduction to drug utilization research 2003.
   Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.
   PubMed Web of Science ®Google Scholar
• Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117–122.
   PubMedGoogle Scholar
• Romppainen T, Rikala M, Aarnio E, et al. Measurement of statin exposure in the absence of information on prescribed doses. Eur J Clin Pharmacol. 2014;70(10):1275–1276.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209.
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449–457.
   PubMed Web of Science ®Google Scholar
• Romagnoli A, Santoleri F, Costantini A. Long-acting injectable vs oral antipsychotics: adherence, persistence and switching over three years of real-life analysis. Curr Clin Pharmacol. 2020; Ahead of print.
   Web of Science ®Google Scholar
• Dorais M, Chirovsky D, Ambegaonkar B, et al. Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Can J Cardiol. 2010;26(7):e229-35–e235.
   PubMed Web of Science ®Google Scholar
• Virani SS, Akeroyd JM, Nambi V, et al. Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk): insights from the department of veterans affairs. Circulation. 2017;135(25):2572–2574.
   PubMed Web of Science ®Google Scholar
• Virani SS, Woodard LD, Akeroyd JM, et al. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American college of cardiology/American heart association cholesterol management guidelines. Clin Cardiol. 2014;37(11):653–659.
   PubMed Web of Science ®Google Scholar
• Deshpande S, Quek RG, Forbes CA, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin. 2017;33(4):769–778.
   PubMed Web of Science ®Google Scholar
• Latry P, Molimard M, Dedieu B, et al. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord. 2011;11:46.
   PubMed Web of Science ®Google Scholar
• Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59(5):564–573.
   PubMed Web of Science ®Google Scholar
• De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–146.
   PubMed Web of Science ®Google Scholar
• De Smedt D, Annemans L, De Backer G, et al. Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. Int J Cardiol. 2018;272:20–25.
   PubMed Web of Science ®Google Scholar
• Reiner Z, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries–findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243–250.
   PubMed Web of Science ®Google Scholar